OR WAIT null SECS
December 30, 2015
BASF and Sumitomo Chemical explore in vitro system for chemical safety evaluation.
December 02, 2015
A strong API market is expected in 2016 despite fewer new drug approvals.
November 30, 2015
The ReactoMate Datum controlled lab reactor system accommodates a range of vessel sizes.
November 26, 2015
Ash Stevens has received FDA’s approval to manufacture Takeda’s multiple myeloma drug, ixazomib, at its facility in Riverview, Michigan.
November 05, 2015
BASF’s new multi-product amines plant in Ludwigshafen, Germany meets growing demand for amines in various applications, including pharmaceuticals.
November 02, 2015
The Transform hydrate-able film from Lubrizol LifeSciences is compatible with a range of APIs.
Efficient syntheses are possible using multi-component and cross-dehydrogenative, heteroaromatic C-H silylation reactions.
October 20, 2015
Athenex will build two facilities for high-potency, oncology API ingredients in Chongqing, China.
October 19, 2015
Hovione is investing in specialized formulation capabilities, beginning with the acquisition of a formulation facility adjacent to the current process chemistry and particle engineering facility in Loures, Portugal, the company announced on Oct. 19, 2015. This acquisition is a strategic investment to further boost development and manufacturing capabilities for both inhalation and oral dosage forms.
October 08, 2015
Grace and Formac Pharmaceuticals have announced SilSol 6035 Mesoporous Silica Gel, the first silica in the Grace silica-based drug delivery platform. The silica gel is the result of a multi-year collaboration between the companies.The platform was engineered to offer a new drug delivery option for APIs with poor aqueous solubility (BCS class 2 compounds), Grace reports and combines the company’s expertise in mesoporous silica gel and novel application methods to accelerate the screening and development of stable, amorphous-based systems.